S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial

Axel Dignass; Silvio Danese; Katsuyoshi Matsuoka; Marc Ferrante; Millie Long; Isabel Redondo; Theresa Hunter Gibble; Richard Moses; Xingyuan Li; Nathan Morris; Catherine Milch; Maria T. Abreu

doi:10.14309/01.ajg.0000859776.67292.10

Back

S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial

Journal article

Open access

Peer reviewed

S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial

Axel Dignass, Silvio Danese, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Theresa Hunter Gibble, Richard Moses, Xingyuan Li, Nathan Morris, …

The American journal of gastroenterology, Vol.117(10S), pp.e558-e558

2022-10

DOI: https://doi.org/10.14309/01.ajg.0000859776.67292.10

Appears in Miller School of Medicine - Latest Publications

Files and links (1)

url

https://doi.org/10.14309/01.ajg.0000859776.67292.10View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial
Creators: Axel Dignass
Silvio Danese
Katsuyoshi Matsuoka
Marc Ferrante
Millie Long
Isabel Redondo
Theresa Hunter Gibble
Richard Moses
Xingyuan Li
Nathan Morris
Catherine Milch
Maria T. Abreu
Publication Details: The American journal of gastroenterology, Vol.117(10S), pp.e558-e558
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Gastroenterology
Language: English
Resource Type: Journal article
Record Identifier: 991031786774002976